APUS· Health Care› Drug Manufacturers - Specialty & Generic

Apimeds Pharmaceuticals US, Inc.

Stage 4 · Declining · week 20

As of Oct 22, 2026, Apimeds Pharmaceuticals US is in Stage 4, the downtrend phase, now in week 20 (since Jun 3, 2026). It closed at $3.16, 91.9% below its 52-week high and below its 200-day average, which is falling.

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. More about the company

$3.16

-0.21% today

$4.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Accelerating ⇈

Edge

—

Is APUS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2025-05-09 → 2026-10-22

S? 42w

S4 6w

S1 8w

S4 20w

2025-05-092026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 6w → S1 8w → S4 20w current

Total tracked: 76 weeks across 4 stage runs.

APUS among Drug Manufacturers - Specialty & Generic75th of 84 by relative strength

All 84 →

Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	CPIXCumberland Pharmaceuticals Inc.	Stage 2 · wk 23	98	+6.8%
2	ETONEton Pharmaceuticals, Inc.	Stage 2 · wk 30	97	−10.1%
3	ANIKAnika Therapeutics Inc.	Stage 2 · wk 15	96	+3.5%
4	IRWDIronwood Pharmaceuticals, Inc. Class A	Stage 3 · wk 3	96	−16.4%
5	TEVATeva Pharmaceutical Industries Limited	Stage 2 · wk 9	95	+3.1%
6	AMRXAmneal Pharmaceuticals, Inc. Class A	Stage 2 · wk 19	95	+5.9%
7	KNSAKiniksa Pharmaceuticals International, plc Class A	Stage 2 · wk 73	95	+6.2%
8	AMLXAmylyx Pharmaceuticals, Inc.	Stage 2 · wk 15	93	−6.6%
…75	APUSApimeds Pharmaceuticals US, Inc.	Stage 4 · wk 20	10	+38.0%

vs 52W High

-91.9%

$1.60 lo$38.95 hi

91.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 20

1w13w26w

Week 20, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-72.1%

200 DMA: $11.32 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.01x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↑ ⇈

Short-term trend rising strongly, and accelerating

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+38.0%

-44.1%

-83.2%

YTD

-81.0%

-83.4%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 20 · Vol 0.01x

2026-10-21S4

Wk 20 · Vol 0.03x

2026-10-20S4

Wk 20 · Vol 0.01x

2026-10-19S4

Wk 20 · Vol 0.02x

2026-10-16S4

Wk 19 · Vol 0.01x

2026-10-15S4

Wk 19 · Vol 0.02x

2026-10-14S4

Wk 19 · Vol 0.05x

2026-10-13S4

Wk 19 · Vol 0.07x

2026-10-12S4

Wk 19 · Vol 0.29x

2026-10-09S4

Wk 18 · Vol 0.71x

2026-10-08S4

Wk 18 · Vol 0.24x

2026-10-07S4

Wk 18 · Vol 5.30x

Moving averages & range

50 DMA

$3.86

200 DMA

$11.32

52W High

$38.95

52W Low

$1.60

5D Low

$3.16

Resistance levels (recent highs)

20d High

$7.25

60d High

$7.25

120d High

$30.00

250d High

$38.95

Next resistance

+129.4%

to 20d High

Dividend Yield

0.00%

P/B 4.9

Apimeds Pharmaceuticals US: quick answers

What stage is Apimeds Pharmaceuticals US in?

As of Oct 22, 2026, Apimeds Pharmaceuticals US (APUS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 3, 2026 and is in week 20. What the four stages mean

Is Apimeds Pharmaceuticals US in an uptrend?

No. Apimeds Pharmaceuticals US is in a Stage 4 downtrend. It trades 72.1% below its 200-day average, which is falling.

How far is Apimeds Pharmaceuticals US from its 52-week high?

Apimeds Pharmaceuticals US closed at $3.16 on Oct 22, 2026, 91.9% below its 52-week high of $38.95. Its 52-week low is $1.60.

How has Apimeds Pharmaceuticals US performed over the past year?

As of Oct 22, 2026, Apimeds Pharmaceuticals US is down 83.4% over the past year and down 81.0% so far in 2026.

Which sector and industry is Apimeds Pharmaceuticals US in?

Apimeds Pharmaceuticals US is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.